Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + PDT vs Bevacizumab in Neovascular AMD
NCT00696592Phase 2Withdrawn
- Sponsor
- Università di Padova
- Start
- Jan 2007
- Primary completion
- Jan 2008
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of verteporfin in neovascular age-related macular degeneration (NVAMD), sponsored by Università di Padova. Planned start Jan 2007; status: withdrawn.
02
Drugs
verteporfin
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00696592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696592.